Maillard reaction products in the Escherichia coli-derived therapeutic protein interferon alfacon-1

Annals of the New York Academy of Sciences

Volumn 1126, Issue , 2008, Pages 181-184

  Mironova, Roumyana ^a   Sredovska, Angelina ^a   Ivanov, Ivan ^a   Niwa, Toshimitsu ^b  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Bulgaria)

^b NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Advanced glycation end products; Adverse events; Antidrug antibodies; Consensus interferon; Glycation; Interferon alfacon 1; Maillard reaction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CONSENSUS INTERFERON;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BIOACCUMULATION; CONFERENCE PAPER; CROSS LINKING; DRUG IMPURITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GLYCATION; IMMUNOREACTIVITY; PROTEIN DEGRADATION; PROTEIN ENGINEERING; WESTERN BLOTTING;

ESCHERICHIA COLI;

EID: 42549091934     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1433.006     Document Type: Conference Paper

References (15)

1. 1 Schellekens, H. 2003. Immunogenicity of therapeutic proteins. Nephrol. Dial. Transplant. 18: 1257–1259.
2. 2 Dioun, A.F. et al. 1998. IgE‐mediated allergy and desensitization to factor IX in hemophilia B. J. Allergy Clin. Immunol. 102: 113–117.
3. 3 Stein, D.F. et al. 2001. Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C. Dig. Dis. Sci. 46: 530–535.
4. 4 Hillier, A.E. et al. 2006. Consensus interferon induced interstitial pneumonitis in a patient with HCV. Am. J. Gastroenterol. 101: 200–202.
5. 5 Siewert, E. et al. 2005. Cutaneous mucinosis and skin necrosis complicates interferon alfacon‐1 (consensus interferon) treatment of chronic hepatitis C. Eur. J. Med. Res. 10: 63–67.
6. 6 Dimitroulopoulos, D. et al. 2004. Immune thrombocytopenic purpura in a patient treated with interferon alfacon‐1. J. Viral. Hepat. 11: 477–478.
7. 7 Mazziotti, G. et al. 2002. Temporal relationship between the appearance of thyroid autoantibodies and development of destructive thyroiditis in patients undergoing treatment with two different type‐1 interferons for HCV‐related chronic hepatitis: a prospective study. J. Endocrinol. Invest. 25: 624–630.
8. 8 Mironova, R. et al. 2003. Glycation and post‐translational processing of human interferon‐gamma expressed in Escherichia coli. J. Biol. Chem. 278: 51068–51074.
9. 9 Niwa, T. et al. 1996. Amyloid beta 2‐microglobulin is modified with N epsilon‐(carboxymethyl)lysine in dialysis‐related amyloidosis. Kidney Int. 50: 1303–1309.
10. 10 Niwa, T. et al. 1997. Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. Clin. Invest. 99: 1272–1280.
11. 11 Blatt, L. et al. 1996. The biologic activity and molecular characterization of a novel synthetic interferon‐alpha species, consensus interferon. J. Interferon Cytokine Res. 16: 489–499.
12. 12 Suzuki, H. & Tango, T. 2002. A multicenter, randomized, controlled clinical trial of interferon alfacon‐1 in comparison with lymphoblastoid interferon‐alpha in patients with high‐titer chronic hepatitis C virus infection. Hepatol. Res. 22: 1–12.
13. 13 Uribarri, J. et al. 2005. Diet‐derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann. N.Y. Acad. Sci. 1043: 461–466.
14. 14 Maleki, S.J. et al. 2000. The effects of roasting on the allergenic properties of peanut proteins. J. Allergy Clin. Immunol. 106: 763–768.
15. 15 Bierhaus, A. et al. 2001. Diabetes‐associated sustained activation of the transcription factor nuclear factor‐kappaB. Diabetes 50: 2792–2808.